Top-Rated StocksTop-RatedNASDAQ:MAZE Maze Therapeutics (MAZE) Stock Price, News & Analysis $25.38 -0.09 (-0.33%) As of 12:20 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Maze Therapeutics Stock (NASDAQ:MAZE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Maze Therapeutics alerts:Sign Up Key Stats Today's Range$25.13▼$26.2550-Day Range$25.47▼$51.8352-Week Range$8.24▼$53.65Volume111,499 shsAverage Volume736,966 shsMarket Capitalization$1.26 billionP/E RatioN/ADividend YieldN/APrice Target$66.00Consensus RatingBuy Company Overview Maze Therapeutics, Inc. (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic. Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas. By integrating large‐scale genetic datasets with functional genomics assays, the company seeks to uncover previously unrecognized pathways that can be modulated by small molecules or biologics. Its target selection strategy is designed to deliver higher confidence in clinical proof‐of‐concept studies, and Maze’s research collaborations with academic and industry partners support the advancement of its most promising candidates through preclinical and early clinical stages. Headquartered in South San Francisco, California, Maze Therapeutics operates within a vibrant biotech cluster and draws on a network of scientific advisors and strategic collaborators worldwide. The company is led by a management team with extensive experience in genomics, drug development and translational research. By focusing on genetically validated targets and a disciplined go-to-clinic approach, Maze aims to bring transformative therapies to patients in need while creating value for its shareholders.AI Generated. May Contain Errors. Read More Maze Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreMAZE MarketRank™: Maze Therapeutics scored higher than 67% of companies evaluated by MarketBeat, and ranked 233rd out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingMaze Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 8 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialMaze Therapeutics has a consensus price target of $66.00, representing about 160.0% upside from its current price of $25.39.Amount of Analyst CoverageMaze Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Maze Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Maze Therapeutics are expected to decrease in the coming year, from ($2.59) to ($3.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Maze Therapeutics is -7.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Maze Therapeutics is -7.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMaze Therapeutics has a P/B Ratio of 3.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.64% of the float of Maze Therapeutics has been sold short.Short Interest Ratio / Days to CoverMaze Therapeutics has a short interest ratio ("days to cover") of 3.77, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Maze Therapeutics has recently decreased by 2.43%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMaze Therapeutics does not currently pay a dividend.Dividend GrowthMaze Therapeutics does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.89 News SentimentMaze Therapeutics has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Maze Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 7 people have searched for MAZE on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.MarketBeat Follows8 people have added Maze Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Maze Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,955,775.00 in company stock.Percentage Held by InstitutionsMaze Therapeutics has minimal institutional ownership at this time.Read more about Maze Therapeutics' insider trading history. Receive MAZE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Maze Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MAZE Stock News HeadlinesMaze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 FinancialsMay 7 at 10:05 AM | fool.comAtul Dandekar Sells 7,500 Shares of Maze Therapeutics (NASDAQ:MAZE) StockMay 2, 2026 | insidertrades.comThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being built at a classified government facility in Tennessee could make today's leading AI models obsolete overnight. He compares it to the iPhone moment that wiped out Nokia, BlackBerry, and Motorola. When this machine comes online, it will reportedly accelerate AI breakthroughs 360-fold - compressing five years of progress into five days. Navellier has identified specific stocks he'd sell before this hits, and one ticker he'd buy before May 5th.May 8 at 1:00 AM | InvestorPlace (Ad)What Makes Maze Therapeutics (MAZE) One of the Best Oversold Small-Cap Stocks to BuyApril 26, 2026 | insidermonkey.comMaze Therapeutics Rings the Nasdaq Stock Market Closing BellApril 24, 2026 | nasdaq.comMaze Therapeutics prices $150 million equity offeringApril 22, 2026 | tipranks.comMaze Therapeutics prices $150M equity offeringApril 22, 2026 | seekingalpha.comMaze Therapeutics Prices Public Offering of 5,540,000 Shares at $23.50 Per Share, Aiming for $150 Million in Gross ProceedsApril 21, 2026 | quiverquant.comQSee More Headlines MAZE Stock Analysis - Frequently Asked Questions How have MAZE shares performed this year? Maze Therapeutics' stock was trading at $41.43 on January 1st, 2026. Since then, MAZE stock has decreased by 38.7% and is now trading at $25.3850. How were Maze Therapeutics' earnings last quarter? Maze Therapeutics, Inc. (NASDAQ:MAZE) announced its quarterly earnings results on Wednesday, March, 25th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.08. When did Maze Therapeutics IPO? Maze Therapeutics (MAZE) raised $140 million in an IPO on Friday, January 31st 2025. The company issued 8,750,000 shares at $15.00-$17.00 per share. Who are Maze Therapeutics' major shareholders? Top institutional investors of Maze Therapeutics include Candriam S.C.A. (0.56%), Bank of New York Mellon Corp (0.15%), Y Intercept Hong Kong Ltd (0.04%) and Ground Swell Capital LLC (0.03%). Insiders that own company stock include Harold Bernstein, Amy Bachrodt, Atul Dandekar and Richard H Scheller. View institutional ownership trends. How do I buy shares of Maze Therapeutics? Shares of MAZE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings3/25/2026Today5/08/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 MAZE's financial health is in the Yellow zone, according to TradeSmith. MAZE has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MAZE Previous SymbolNASDAQ:MAZE CIK1842295 WebN/A Phone(650) 850-5070FaxN/AEmployees121Year Founded2018Price Target and Rating Average Price Target for Maze Therapeutics$66.00 High Price Target$110.00 Low Price Target$46.00 Potential Upside/Downside+160.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($3.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$131.12 million Net MarginsN/A Pretax MarginN/A Return on Equity-40.70% Return on Assets-36.03% Debt Debt-to-Equity RatioN/A Current Ratio15.50 Quick Ratio15.50 Sales & Book Value Annual Sales$167.50 million Price / Sales7.54 Cash FlowN/A Price / Cash FlowN/A Book Value$7.38 per share Price / Book3.44Miscellaneous Outstanding Shares49,760,000Free FloatN/AMarket Cap$1.26 billion OptionableN/A Beta2.50 Social Links Don't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:MAZE) was last updated on 5/8/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredOne executive order. The biggest wealth transfer of your lifetime.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | Sponsored‘Please’: OpenAI CEO Sam Altman Begs Small Company for HelpSpaceX 'Dark Energy' Replaces Foreign Oil For years, we've been told SpaceX is a rocket company. But accord...Altimetry | SponsoredIs the SpaceX IPO “Rigged?”The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - pre...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maze Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maze Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
